



HAL
open science

BRCA1 expression during prenatal development of the human mammary gland

Frédérique Magdinier, Nicole Dalla Venezia, Gilbert M. Lenoir, Lucien Frappart, Robert Dante

► **To cite this version:**

Frédérique Magdinier, Nicole Dalla Venezia, Gilbert M. Lenoir, Lucien Frappart, Robert Dante. BRCA1 expression during prenatal development of the human mammary gland. *Oncogene*, 1999, 18 (27), pp.4039-4043. 10.1038/sj.onc.1202780 . hal-01663803

HAL Id: hal-01663803

<https://amu.hal.science/hal-01663803>

Submitted on 14 Dec 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SHORT REPORT

***BRCA1* expression during prenatal development of the human mammary gland**

Frédérique Magdinier¹, Nicole Dalla Venezia¹, Gilbert M Lenoir¹, Lucien Frappart¹ and Robert Dante^{*1}

¹Laboratoire de Génétique, UMR 5641 CNRS, Domaine Rockefeller, UCBL1, 8 avenue Rockefeller, 69373 Lyon cedex 08, France

Germ-line alterations of *BRCA1* are associated with elevated risk of breast cancer. Evidence for the involvement of *Brcal* in cellular differentiation and morphogenesis has been obtained in mouse models during embryogenesis. Although the presence of well-conserved functional domains might suggest a similar function for both human and mouse genes, very few data on *BRCA1* expression in human fetal tissues are available. We have, therefore, investigated the expression of *BRCA1* in the mammary gland from human female fetuses aged between 15 and 33 weeks. Quantification of *BRCA1* transcripts, using a competitive reverse transcriptase PCR method, indicates a progressive decrease in *BRCA1* expression with increasing fetal age between the 15th and 30th week of gestation. Subsequently, the amount of *BRCA1* transcripts becomes similar to that found in adult mammary gland. Analysis of *BRCA1* protein revealed, in fetal samples, a 220 kDa band corresponding to the 220 kDa *BRCA1* protein described in human cell lines. These later experiments confirm that the relative level of the 220 kDa *BRCA1* protein is highest in the early stages of mammary gland development. The temporal patterns of *BRCA1* expression in human fetuses suggest a role for *BRCA1* in the morphogenesis and differentiation of the human mammary gland.

Keywords: *BRCA1*; mRNA; protein; prenatal development; human mammary gland

Familial risk of breast cancer is associated with germ-line alterations of several genes including *p53*, *BRCA1*, *BRCA2* and *pTEN* (Ellisen and Haber, 1998). Among these genes, *BRCA1* seems to be responsible for predisposition in the large majority of families with breast and ovarian cancer and about half of families with breast cancer only (Friedman *et al.*, 1994; Easton *et al.*, 1997), germ-line alterations of *BRCA1* conferring a life time risk of 40% for ovarian cancers and 80–90% for breast cancers (Ford *et al.*, 1994).

BRCA1 gene encodes for a protein of 1863 amino acids and the corresponding 220 kDa protein has been detected in human cell lines using multiple *BRCA1*-specific antibodies (Chen *et al.*, 1995; Scully *et al.*, 1996). The amino-terminal portion of this protein contains a RING finger domain which has been

previously described in several other proteins exhibiting transactivation activity (Wu *et al.*, 1996) and the C-terminal region possess a BRCT domain also found in several proteins involved in DNA repair (Bork *et al.*, 1997; Callebaut and Mornon 1997; Saka *et al.*, 1997). In addition, recent findings describing *BRCA1*/*Rad51*/*BARD1*-multiprotein complexes and their behavior following genotoxic insult, suggest a role for *BRCA1* in the DNA damage-dependent cell cycle checkpoint response (Wu *et al.*, 1996; Scully *et al.*, 1997a,b). However, the presence of a transactivation domain in *BRCA1* and its stable association via RNA helicase A with RNA Polymerase II holoenzyme (Anderson *et al.*, 1998) indicate that *BRCA1* might also be involved in the regulation of transcription. These two hypotheses, which are not mutually exclusive, stress that *BRCA1* may have an important role in cellular differentiation and proliferation.

It is likely that *BRCA1* acts as a tumor suppressor gene (Smith *et al.*, 1992). Indeed, in breast cancers linked to *BRCA1*, as expected for a tumor suppressor gene, allelic deletions at this locus invariably involve the wild type allele (Smith *et al.*, 1992; Neuhausen and Marshall, 1994).

In sporadic human breast cancers, despite the fact that somatic mutations have not been detected (Futreal *et al.*, 1994; Merajver *et al.*, 1995), alterations of the *BRCA1* mRNA level have been observed. Microdissections of biopsies from sporadic invasive breast tumors have shown a decrease in *BRCA1* expression in the tumoral component of the samples (Thompson *et al.*, 1995). In addition, quantification of *BRCA1* mRNA molecules indicates that the majority of the tumors analysed (33 out of 37) exhibit a 10–12-fold decrease in *BRCA1* mRNA compared to that observed in normal breast tissue (Magdinier *et al.*, 1998), suggesting that this down regulation might be a feature of sporadic breast cancers, since a decrease in the *BRCA1* mRNA level is observed in all histologic types of tumors analysed.

Evidence for the involvement of *BRCA1* in cellular growth and differentiation has also been obtained in mouse models. In transgenic mice, homozygous disruption of the *Brcal* gene results in embryonic lethality (Hakem *et al.*, 1996). The progressive changes in *Brcal* expression during mouse embryogenesis also imply a role for *Brcal* in the differentiation process. In mouse embryos a relative high expression of *Brcal* in rapidly proliferating tissues undergoing differentiation has been found (Marquis *et al.*, 1995). This up-regulation is correlated with PCNA (proliferating cell nuclear antigen) positive staining (Blackshear *et al.*, 1998) and seems to be associated with the terminal

*Correspondence: R Dante

Received 6 August 1998; revised 2 March 1999; accepted 2 March 1999

differentiation of ectodermally and mesodermally derived tissues in mice (Lane *et al.*, 1995).

Variations in *Brcal* expression were also observed in adult mouse tissues during the postnatal mammary gland development associated with pregnancy (Lane *et al.*, 1995; Blackshear *et al.*, 1998) and an up-regulation of *Brcal*, in the adult mammary gland, occurs during the ductular proliferation and morphogenesis stage (Blackshear *et al.*, 1998). In mice *Brcal* expression seems to be, therefore, closely associated with the differentiation of the mouse mammary gland.

Although the presence of well-conserved functional domains, such as the RING finger structure and the BRCT domain, might suggest a similar function for both human and mouse genes, very few data on the *BRCA1* expression in human fetal tissues are available. We have, therefore, investigated the expression of *BRCA1* in human fetal mammary gland.

Nascent breast tissue sections of human female fetuses corresponding to the major stages of prenatal development of the mammary gland (between 19th week of gestation and newborn) were examined by light microscopy (Figure 1). During fetal life, descriptive embryology has demonstrated several successive stages of development beginning during the 4th week of gestation (Dawson, 1934). One of the earliest stages of mammary gland development (between the 6th and 8th week of gestation) is the

formation of a lens-shaped structure composed of several layers of epidermal cells surrounded by dense mammary mesenchyme. This bud elongates rapidly (8–15 weeks) forming the mammary sprout which subsequently (16–19 weeks) invades the fat pad precursor tissue composed of islets of preadipocytes (Figure 1a and b). This stage is followed by an initial branching of the mammary sprout (Figure 1c). Then, a funnel-shaped outline is formed (Figure 1d), the mouth of this funnel, partly filled with cornified cells, is directed towards the surface (each mammary gland averages 15–20 branched ducts at birth).

The steady state level of *BRCA1* mRNA was determined in fetal mammary tissue samples (12 of female fetuses analysed) spanning the fetal life between the 15th and 33rd week of gestation, *BRCA1*

Table 1 Quantification of *BRCA1* mRNA during human fetal mammary gland development by competitive RT-PCR assay

Mammary gland samples	BRCA1 mRNA	n
Fetal samples (weeks of gestation)		
15th	563	1
19th	451 ^a (409, 493)	1
21st	420 ^a (500, 434, 362)	3
22nd	250	1
24th	216 ^a (230, 202)	2
25th	230 (230, 230)	1
26th	200	1
30th	143 ^a (133, 153)	1
33rd	147	1
4-month-old infant	156	1
Adult	179.2 ^a ± 40.8	6

BRCA1 mRNA level was determined by a competitive RT-PCR assay (Riberas *et al.*, 1997) and expressed as the number of *BRCA1* mRNA molecules × 10⁻³ μg of total RNA. When several determinations are performed, the values obtained are indicated in brackets and ^a indicates the mean value; n indicates the number of samples analysed. The values for adult mammary glands have been previously determined (Magdinier *et al.*, 1998)




Figure 1 Morphological changes of the mammary gland in human females during prenatal development. (a) Mammary sprout of a 19-week-old female human fetus. Lobular structure of the fat pad is seen below the mammary rudiment. (b) Mammary sprout of 27-week-old female human fetus. (c) Mammary sprout of 30-week-old female human fetus. (d) Mammary gland of a human female newborn (detail). The mammary epithelial rudiment forms a funnel-shaped outline. The mouth of the funnel is directed towards the surface and is filled with cornified cells (each mammary gland averages 15–20 branched ducts at birth). cc, cornified cells; d, mammary ducts; e, mammary epithelium; fp, fat pad; mm, dense mammary mesenchyme. Bar = 50 μm




Figure 2 RT-PCR assays of *BRCA1* transcripts during human mammary gland development. The number of *BRCA1* mRNA molecules/μg of total RNA was plotted against the gestational age of the mammary gland. (a) schematic representation of the mammary gland (Girod and Czyba, 1970) of a 16-week-old female fetus. (b) 16–20 week of gestation, occurrence of the branching stage. (c) 20–32 week of gestation. Subsequently, the mammary gland follows the general growth of the body

transcripts were also analysed in a tissue sample corresponding to the postnatal stage, 4 months after birth (values obtained are shown in Table 1). *BRCA1* mRNA was quantitated using a competitive RT-PCR assay (Ribieras *et al.*, 1997; Magdinier *et al.*, 1998). This PCR method measures the absolute amount of a specific mRNA in a RNA sample, the competing RNA acting as an internal control for the reverse transcription and PCR reactions. This kinetic study indicates that the amount of *BRCA1* mRNA molecules/ μg of total RNA is 4–5-fold higher in the first stages of prenatal development analysed (between the 15th and 21st week of gestation) than the level observed in adult mammary tissues. A major splice variant of the *BRCA1* transcript has been described in human cell lines and tissues (Lu *et al.*, 1996; Thakur *et al.*, 1997; Wilson *et al.*, 1997). In addition, the RT-PCR experiments, performed with primers specific for the *BRCA1*- $\Delta 11\text{b}$ transcript (Wilson *et al.*, 1997), indicated that the amount of this transcript parallels the amount of total *BRCA1* transcripts quantified by the competitive RT-PCR assays described in these report (data not shown).

Thus, *BRCA1* mRNA level decreases progressively during the canalization stage, which occurs between the 20th and 33rd week of fetal life. At the 30th week of gestation the number of mRNA molecules becomes similar to the level observed in adult mammary gland (Figure 2). After this stage, and until the approach of

puberty, the mammary gland follows the general growth of the body and the *BRCA1* mRNA level remains constant throughout the samples analysed. These data, therefore, indicate that the expression of *BRCA1* is associated with the prenatal development of the human mammary gland.

In order to determine the potential relationship between the amount of transcripts and *BRCA1* protein, Western blot experiments were performed from whole cell extracts (WCE) of human breast cell lines (HBL-100, MCF-7, BT-20) previously analysed for their *BRCA1* mRNA content (Ribieras *et al.*, 1997). The *BRCA1* proteins were detected using an affinity purified antibody raised against a peptide (aminoacids 1345 to 1362) chosen within the exon 11 of *BRCA1*. A strong band of 220 kDa is detected in these cell lines (Figure 3), as expected since several authors have described this 220 kDa *BRCA1* protein in human cell lines (Chen *et al.*, 1995; Scully *et al.*, 1996). Quantification of the signal obtained for the 220 kDa protein indicated a ratio similar to that obtained in RT-PCR assays (HBL 100/MCF7/BT-20; 1/0.56/0.24 compared with 1/0.56/0.16 for *BRCA1* mRNA content, taking 1 for HBL-100 cell line).

We have, therefore, analysed *BRCA1* protein in some tissue samples spanning crucial stages of mammary gland development, i.e. 21st, 25th, 26th and 30th week of gestation. *BRCA1* proteins were, also, investigated in an adult mammary gland and in the human breast cell lines. Immunoblots revealed a 220 kDa protein in fetal and adult mammary tissues




Figure 3 *BRCA1* expression in human breast cell lines. (a) Immunoblot analysis of the 220 kDa *BRCA1* protein; whole cell extracts from human breast cell lines, HBL-100 cells (lane 1), MCF-7 cells (lane 2) and BT-20 cells (lane 3) were separated on a SDS-4 to 12% linear gradient polyacrylamide gel. *BRCA1* proteins were probed using the 5HU (1:60 diluted) polyclonal antibody directed against the aminoacids 1345 to 1362 of the *BRCA1* protein and visualized with the ECL chemiluminescent detection kit (Amersham Life Science, France). (b) The signal corresponding to the *BRCA1* band (220 kDa) was normalized, taking 1 for the signal corresponding to the HBL-100 cell lines. Autoradiograms were scanned (UMAX) and the intensity of the band corresponding to the 220 kDa *BRCA1* protein was determined using image analyser software (Wayne Rasband, NIH)




Figure 4 Immunoblot analysis of *BRCA1* in fetal mammary gland. (a) WCE from four mammary gland samples corresponding to the 21st week (lane 1), 25th week (lane 2), 26th week (lane 3), 30th week of gestation (lane 4) and from one sample of adult mammary gland (lane 5) were separated on a SDS-4 to 12% linear gradient polyacrylamide gel. *BRCA1* proteins were probed using the 5HU polyclonal antibody and visualized with the ECL chemiluminescent detection kit (Amersham Life Science, France). (b) The signal corresponding to the *BRCA1* band (220 kDa) was normalized, taking 1 for the signal corresponding to the adult tissue, as described in the legend of Figure 3

(Figure 4a) indicating that the BRCA1 protein, in human mammary tissues, exhibits an apparent molecular weight similar to that observed in human cell lines (Chen *et al.*, 1995; Scully *et al.*, 1996).

The relative intensity of the bands corresponding to the 220 kDa BRCA1 protein (Figure 4b) indicates that this protein is expressed at a high level between the 21st and the 26th week of fetal life and then, in the 30th week of gestation, this level becomes similar to that observed in the adult mammary gland sample. Control experiments performed with monoclonal antibodies directed against the N-terminal part of the BRCA1 protein (Scully *et al.*, 1996) also indicated, a progressive decrease between the 21st week and 30th week of gestation (data not shown).

Taken together these data indicate that *BRCA1* expression is closely associated with the differentiation of the human mammary gland during fetal life. In addition, quantification of *BRCA1* transcripts in kidney, spleen, adrenal gland, lung and pancreas tissue samples from fetuses aged 24 and 30 weeks, indicated that the level of *BRCA1* mRNA is lower at the 24th week than in the 30th week (unpublished data). Thus, the temporal pattern of *BRCA1* expression in fetal human mammary tissues does not seem to be a consequence of a general activation of this gene. Consistent with this hypothesis, it has been shown in mice embryos, using *in situ* hybridization methods, that the activation of *Brcal* is dependant on the stage of embryo development and on the tissues (Marquis *et al.*, 1995; Blackshear *et al.*, 1998).

In mice, RNase protection assays and Northern blot analysis have shown a 5–10-fold increase in *Brcal* transcripts during pregnancy (Lane *et al.*, 1995; Marquis *et al.*, 1995). This up-regulation seems to be

associated with ductular and glandular proliferation (Blackshear *et al.*, 1998) during the first stages of pregnancy. Then, during alveolar epithelial differentiation, *BRCA1* mRNA becomes nearly undetectable returning, after mammary gland regression, to the level found in virgin mice (Lane *et al.*, 1995; Marquis *et al.*, 1995; Rajan *et al.*, 1997; Blackshear *et al.*, 1998). *In situ* hybridization has shown that the increase in *Brcal* mRNA level occurs in epithelial cells and in adjacent stromal fibroblasts (Blackshear *et al.*, 1998). Since both cell types participate in the morphogenesis of the mammary gland (Sakakura, 1987), all of these data strongly suggest a close association between the postnatal development of mouse mammary gland and *BRCA1* expression.

Although the biological function of BRCA1 has not yet been fully determined, evidence for an involvement of *BRCA1* in cell cycle checkpoints has been reported by several authors (for review see Bertwistle and Ashworth, 1998). This up-regulation during mammary gland development might suggest that BRCA1 exerts important checkpoint control functions during critical developmental stages.

Acknowledgements

We would like to thank Marc Billaud and Valerie James for discussion and critical reading of the manuscript. F Magdinier is a recipient of the fellowship from the Ligue Nationale contre le Cancer. The present work was supported by the Ligue Nationale contre le Cancer, Comité de Saône et Loire, the Association pour la Recherche contre le Cancer and the CNRS (programme Physique et Chimie du Vivant).

References

- Anderson SF, Schegel BP, Nakajima T, Wolpin ES and Parvin JD. (1998). *Nat. Genet.*, **19**, 254–256.
- Bertwistle D and Ashworth A. (1998). *Curr. Opin. Genes Dev.*, **8**, 14–20.
- Blackshear PE, Goldsworthy SM, Foley JF, McAllister KA, Bennett M, Collins NK, Bunch DO, Brown P, Wiseman RW and Davis BJ. (1998). *Oncogene*, **16**, 61–68.
- Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF and Koonin EV. (1997). *FASEB J.*, **11**, 68–76.
- Callebaut I and Mornon JP. (1997). *FEBS Lett.*, **400**, 25–30.
- Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Vonhoff D, Osborne CK and Lee WH. (1995). *Science*, **270**, 789–791.
- Chomczynski P and Sacchi N. (1987). *Anal. Biochem.*, **162**, 156–159.
- Dawson EK. (1934). *Ebind. Med. J.*, **41**, 653–682.
- Easton D. (1997). *Nat. Genet.*, **16**, 210–211.
- Ellisen LF and Haber DA. (1998). *Annu. Rev. Med.*, **49**, 425–436.
- Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Haites N, Milner B, Allan L, Ponder BAJ, Peto J, Smith S, Stratton M, Lenoir GM, Feunten J, Lynch H, Arason A, Barkardottir R, Egilsson V, Black DM, Kelsell D, Spurr N, Devillee P, Cornilisse CJ, Varsen H, Birch JM, Skolnick M, Santibanezkoref MS, Teare D, Steel M, Porter D, Cohen BB, Carothers A, Smyth E, Weber B, Newbold B, Boehnke M, Collins FS, Cannon-Albright LA and Goldgar D. (1994). *Lancet*, **343**, 692–695.
- Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE and King MC. (1994). *Nat. Genet.*, **8**, 399–404.
- Futreal PA, Liu QY, Shattuck Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugenstrano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaverfeldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A and Wiseman R. (1994). *Science*, **266**, 120–122.
- Girod C and Czyba JC. (1970). Le placenta, la glande mammaire et la lactation. In: *Cours sur la biologie de la reproduction*. Fascicule II. SIMEP (ed).
- Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J and Mak TW. (1996). *Cell*, **85**, 1009–1023.
- Lane TF, Deng CX, Elson A, Lyu MS, Kozak CA and Leder P. (1995). *Genes Dev.*, **9**, 2712–2722.
- Lu M, Conzen SD, Cole CN and Arrick BA. (1996). *Cancer Res.*, **56**, 4578–4581.
- Magdinier F, Ribieras S, Lenoir GM, Frappart L and Dante R. (1998). *Oncogene*, **17**, 3169–3176.
- Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA and Iglehart JD. (1997). *Oncogene*, **14**, 15–121.

- Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL and Chodosh LA. (1995). *Nat. Genet.*, **11**, 17–26.
- Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber B, Collins FS, Johnston C and Frank TS. (1995). *Nat. Genet.*, **9**, 439–443.
- Neuhausen SL and Marshall CJ. (1994). *Cancer Res.*, **54**, 6069–6072.
- Rajan JV, Marquis ST, Gardner HP and Chodosh LA. (1997). *Dev. Biol.*, **184**, 385–401.
- Ribieras S, Magdinier F, Leclerc D, Lenoir G, Frappart L and Dante R. (1997). *Int. J. Cancer*, **73**, 715–718.
- Russo J and Russo IH. (1987). Development of the human mammary gland. In: *The mammary gland. Development, Regulation, and Function*. Neville MC and Daniel CW (eds). Plenum Press: New York, pp. 67–93.
- Saka Y, Esashi F, Matsusaka T, Mochidas S and Yanagida M. (1997). *Genes Dev.*, **11**, 3387–3400.
- Sakakura T. (1987). Mammary embryogenesis. In: *The mammary gland. Development, Regulation and Function*. Neville MC and Daniel CW (eds). Plenum Press: New York, pp. 37–66.
- Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T and Livingston DM. (1997a). *Cell*, **88**, 265–275.
- Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J and Livingston DM. (1997b). *Cell*, **90**, 425–435.
- Scully R, Ganesan S, Brown M, DeCaprio JA, Cannistra SA, Feunteun J, Schnitt S and Livingston DM. (1996). *Science*, **272**, 123–125.
- Smith SA, Easton DF, Evans DGR and Ponder BAJ. (1992). *Nat. Genet.*, **2**, 128–131.
- Spillman MA and Bowcock A. (1996). *Oncogene*, **13**, 1639–1645.
- Tanner JM. (1962). The development of the reproductive system. In: *Growth at Adolescence*. Tanner JM (ed.), Blackwell Scientific: Oxford, pp. 28–39.
- Thakur S, Zhang HB, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid LM, Couch FJ, Wilson RB and Weber BL. (1997). *Mol. Cell. Biol.*, **17**, 444–452.
- Thompson ME, Jensen RA, Obermiller PS, Page DL and Holt JT. (1995). *Nat. Genet.*, **9**, 444–450.
- Wilson CA, Payton MN, Elliot GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ and Calzone FJ. (1997). *Oncogene*, **14**, 1–16.
- Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM and Baer R. (1996). *Nat. Genet.*, **14**, 430–440.
- Xu CF, Chambers JA and Solomon E. (1997). *J. Biol. Chem.*, **272**, 20994–20997.